Form 4: Cidara Therapeutics Director Mineo Acquires Stock Options
SEC Form 4 Filing
Director Chrysa Mineo reports acquisition of stock options in Cidara Therapeutics.
Summary
- On July 18, 2024, Chrysa Mineo, a director of Cidara Therapeutics, Inc., acquired 2,125 stock options.
- The options have an exercise price of $12.64.
- The options vest on the earlier of the first anniversary of the grant date or the day prior to the Issuer's 2025 annual meeting of stockholders.
- Following the transaction, Mineo directly owns 2,125 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director. While insider buying can be seen as positive, option grants are part of standard compensation packages.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC filing related to insider transactions. It's common for directors and officers to receive stock options as part of their compensation.
Key Dates
| Date | Description |
|---|---|
| 07/18/2024 | Date of transaction: Chrysa Mineo acquired stock options. |
| 07/19/2024 | Date of report: Form 4 filing date. |
| 07/17/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.